Patients prefer patient organizations over pharma companies when it comes to services.

The move to an outcomes model in pharma is real. However, how pharma companies will get there is much less clear.

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

The government's patents on Gilead's Truvada have made plenty of headlines lately, and that's a distraction, Gilead figures.

The longtime leader of the National Institute for Health and Care Excellence will step down in March after 21 years on the job.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin.